Results | Latest & Breaking News on Results | Photos, Videos, Breaking Stories and Articles on Results

you are here: Home News

Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher
Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher
Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher
Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher
Glenmark Pharma Q1 PAT seen up 23.3% YoY to Rs 313.1 cr: KRChoksey
Glenmark Pharmaceuticals Q3 PAT seen up 27.4% YoY to Rs. 190.8 cr: Prabhudas Lilladher
Glenmark Q2 PAT may dip 46% YoY to Rs. 132.8 cr: Emkay
Glenmark Pharma Q1 PAT may dip 44.8% YoY to Rs. 151.7 cr: Prabhudas Lilladher
Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
Glenmark Pharmaceuticals Q4 PAT seen up 30% YoY to Rs. 196.4 cr: Prabhudas Lilladher
Glenmark Q3 PAT seen up 96.7% YoY to Rs. 206.5 cr: Sharekhan
Glenmark Q3 PAT seen up 121.5% YoY to Rs. 232 cr: ICICI Direct
Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila
Glenmark Pharma Q2 PAT seen up 2.8% YoY to Rs. 210 cr: HDFC Securities
Glenmark Q2 PAT may dip 22% YoY to Rs. 167 cr: Sharekhan
Glenmark Q2 PAT seen up 1.7% YoY to Rs. 217.8 cr: ICICI Direct
Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz
Glenmark Pharma Q4 PAT seen up 711.4% YoY to Rs. 170 cr: HDFC Securities
Glenmark Pharma Q4 PAT may dip 27.7% YoY to Rs. 173.7 cr: Edelweiss
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key
Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue
Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key
Not looking at M&A as growth opportunity, would like to grow organically: Glenmark
Have buy rating on Glenmark Pharma: HDFC Securities
Glenmark Pharma Q1 profit seen up 13% at Rs 257 cr, revenue growth may be 17%

English

Markets

News

Personal Finance

Mutual Funds

Commodities

Media

Invest Now

Specials

Glenmark Pharmaceuticals Q1 PAT may dip 41.8% YoY to Rs 178.4 cr: Prabhudas Lilladher

Glenmark Pharmaceuticals Q4 PAT may dip 20.1% YoY to Rs 186.8 cr: Prabhudas Lilladher

Glenmark Pharmaceuticals Q3 PAT seen up 17.8% YoY to Rs 292.4 cr: Prabhudas Lilladher

Glenmark Pharmaceuticals Q2 PAT seen up 18.4% YoY to Rs 269.5 cr: Prabhudas Lilladher

Glenmark Pharma Q1 PAT seen up 23.3% YoY to Rs 313.1 cr: KRChoksey

Glenmark Pharmaceuticals Q3 PAT seen up 27.4% YoY to Rs. 190.8 cr: Prabhudas Lilladher

Glenmark Q2 PAT may dip 46% YoY to Rs. 132.8 cr: Emkay

Glenmark Pharma Q1 PAT may dip 44.8% YoY to Rs. 151.7 cr: Prabhudas Lilladher

Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell

Glenmark Pharmaceuticals Q4 PAT seen up 30% YoY to Rs. 196.4 cr: Prabhudas Lilladher

Glenmark Q3 PAT seen up 96.7% YoY to Rs. 206.5 cr: Sharekhan

Glenmark Q3 PAT seen up 121.5% YoY to Rs. 232 cr: ICICI Direct

Credit Suisse expects strong Q3 quarter for Aurobindo, Torrent Pharma, Cadila

Glenmark Pharma Q2 PAT seen up 2.8% YoY to Rs. 210 cr: HDFC Securities

Glenmark Q2 PAT may dip 22% YoY to Rs. 167 cr: Sharekhan

Glenmark Q2 PAT seen up 1.7% YoY to Rs. 217.8 cr: ICICI Direct

Pharma Q1 preview: Poised for strong performance on rebound of domestic and stable US generics biz

Glenmark Pharma Q4 PAT seen up 711.4% YoY to Rs. 170 cr: HDFC Securities

Glenmark Pharma Q4 PAT may dip 27.7% YoY to Rs. 173.7 cr: Edelweiss

Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key

Glenmark Pharma tanks 9% after disappointing Q3 earnings, US pricing pressure to continue

Pharma Q3 earnings preview - cos brace for challenging quarter, US and India sales hold key

Not looking at M&A as growth opportunity, would like to grow organically: Glenmark

Have buy rating on Glenmark Pharma: HDFC Securities

Glenmark Pharma Q1 profit seen up 13% at Rs 257 cr, revenue growth may be 17%